{"id":"skq1-vehicle-solution","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased intraocular pressure"},{"rate":"null","effect":"Cardiac arrhythmias"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SkQ1 works by accumulating in the mitochondria, where it can neutralize reactive oxygen species and reduce oxidative stress. This is thought to help delay the onset of age-related diseases by protecting cells from damage. By doing so, SkQ1 may help to improve overall healthspan and potentially treat age-related conditions.","oneSentence":"SkQ1 is a mitochondrially-targeted antioxidant that aims to delay the onset of age-related diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:57.208Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry age-related macular degeneration"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT03764735","phase":"PHASE3","title":"Study of SkQ1 as Treatment for Dry-eye Syndrome","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2018-12-06","conditions":"Dry Eye Syndrome","enrollment":452},{"nctId":"NCT04206020","phase":"PHASE3","title":"Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2019-12-20","conditions":"Dry Eye Syndrome","enrollment":610},{"nctId":"NCT02121301","phase":"PHASE2","title":"A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)","status":"COMPLETED","sponsor":"Mitotech, SA","startDate":"2014-04","conditions":"Keratoconjunctivitis Sicca","enrollment":91}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle for SkQ1"],"phase":"phase_3","status":"active","brandName":"SkQ1 Vehicle Solution","genericName":"SkQ1 Vehicle Solution","companyName":"Mitotech, SA","companyId":"mitotech-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SkQ1 Vehicle Solution is being studied as a treatment for Dry Eye Syndrome and Keratoconjunctivitis Sicca in a Phase 3 clinical trial. The study, NCT04206020, is a randomized, double-masked, placebo-controlled trial sponsored by Mitotech, SA.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}